首頁 > 市場調查報告書 > 製藥

生物製劑基因治療學和RNAi

市場調查報告書

商品編碼

1781961

病毒載體疫苗市場（按疾病、按類型、按最終用戶、按國家和地區）－2025 年至 2032 年全球產業分析、市場規模、市場佔有率及預測

Viral Vector Vaccines Market, By Disease, By Type, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日期: 2025年06月04日 | 出版商:

AnalystView Market Insights | 英文 269 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

報告重點

2024 年病毒載體疫苗市場規模價值 8.5043 億美元，2025 年至 2032 年的複合年成長率為 15.93%。

病毒載體疫苗市場-市場動態

傳染病流行率上升推動市場需求

新冠肺炎 (COVID-19)、流感和肝炎等傳染病發生率的上升，推動了對有效疫苗的需求。世界衛生組織 (WHO) 的數據顯示，疫苗每年可預防 200 萬至 300 萬人死亡，凸顯了其在全球健康中的關鍵作用。此外，基因工程的不斷進步促進了更高效病毒載體疫苗的研發。然而，儘管不良反應案例罕見，但仍有報道，導致公眾對此持謹慎態度，預計這將阻礙未來幾年的市場成長。相反，由於醫療基礎設施的改善和疫苗接種意識的提高，發展中地區蘊藏著巨大的成長機會。

病毒載體疫苗市場—關鍵見解

根據我們的研究分析師的分析，預測期內（2025-2032 年）全球市場預計年複合成長率約為 15.93%

根據疾病細分，預計傳染病將在 2024 年佔據最大市場佔有率

根據類型細分，腺病毒是 2024 年的主要類型

按地區分類，北美是 2024 年的主要收入來源

病毒載體疫苗市場-區隔分析：

全球病毒載體疫苗市場根據疾病、類型、最終用戶和地區進行細分。

根據疾病類型，市場分為四類：傳染病、癌症、遺傳性疾病和其他疾病。預計在預測期內，傳染病領域將佔據全球病毒載體疫苗市場的主要佔有率。這種主導地位主要源於全球傳染病的高負擔以及病毒載體平台在開發針對傳染病的疫苗方面已證實的有效性。

根據類型，市場分為五類：腺相關病毒 (AAV)、腺病毒、慢病毒、逆轉錄病毒和其他病毒。預計腺病毒將在預測期內佔據最大的市場佔有率。這主要是因為腺病毒因其強大的免疫原性、攜帶大量基因有效載荷的能力以及快速疫苗開發的適用性而被廣泛應用。

病毒載體疫苗市場—地理洞察

北美地區佔據全球病毒載體疫苗市場的最大佔有率。這一優勢得益於其先進的醫療基礎設施、雄厚的研發投入以及領先的製藥和生物技術公司。此外，預計亞太地區將在全球市場中實現最快的成長，這得益於醫療保健投資的增加、傳染病發病率的上升以及人們對先進治療方案的認知的不斷提高。

病毒載體疫苗市場-競爭格局：

全球對高效快速疫苗的需求不斷成長，推動技術創新和策略性投資。各公司正致力於改進載體設計、提升安全性並擴大生產能力，以滿足不斷成長的需求。與研究機構和政府機構的合作已成為一種常見做法，旨在加速疫苗研發和監管批准。此外，各公司正在拓展產品線，將針對新興傳染病的疫苗納入其中。此外，各公司也正在進行區域擴張和收購，以增強全球影響力並擴大先進疫苗平台的可及性。

介紹
- 按地區分類的細分市場佔有率分析
北美洲
- 概述
- 北美洲病毒載體疫苗主要製造商
- 北美市場規模及預測（按國家/地區）
- 北美市場規模及預測（按疾病）
- 北美市場規模和預測（按類型）
- 北美市場規模和預測（按最終用戶）
- 美國
- 加拿大
歐洲
- 概述
- 歐洲病毒載體疫苗主要製造商
- 歐洲市場規模及預測（按國家/地區）
- 歐洲市場規模及預測（按疾病）
- 歐洲市場規模與預測（按類型）
- 歐洲市場規模和預測（按最終用戶）
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 荷蘭
- 瑞典
- 俄羅斯
- 波蘭
- 歐洲其他地區
亞太地區 (APAC)
- 概述
- 亞太地區病毒載體疫苗主要製造商
- 亞太地區市場規模及預測（依國家）
- 亞太地區市場規模及預測（按疾病）
- 亞太地區市場規模及預測（按類型）
- 亞太地區市場規模及預測（依最終用戶）
- 中國
- 印度
- 日本
- 韓國
- 澳洲
- 印尼
- 泰國
- 菲律賓
- 亞太地區其他地區
拉丁美洲（LATAM）
- 概述
- 拉丁美洲病毒載體疫苗主要製造商
- 拉丁美洲市場規模及預測（按國家/地區）
- 拉丁美洲市場規模及預測（按疾病）
- 拉丁美洲市場規模及預測（按類型）
- 拉丁美洲市場規模及預測（按最終用戶）
- 巴西
- 墨西哥
- 阿根廷
- 哥倫比亞
- 拉丁美洲其他地區
中東和非洲（MEA）
- 概述
- 中東和非洲病毒載體疫苗主要製造商
- MEA 市場規模及預測（依國家/地區）
- MEA 市場規模及預測（依疾病）
- MEA 市場規模和預測（按類型）
- MEA 市場規模和預測（按最終用戶）
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 以色列
- 土耳其
- 阿爾及利亞
- 埃及
- MEA 其餘地區

第 11 章：病毒載體疫苗產業主要供應商分析

競爭儀錶板
- Competitive Benchmarking
- Competitive Positioning
公司簡介
- Advanced Bioscience Laboratories
- Sanofi SA
- CH Boehringer Sohn AG & Ko
- Brammer Bio, LLC
- GE Healthcare
- Creative Biogene
- Pfizer Inc.
- Moderna Inc.
- Sinovac Biotech Ltd.
- CSL Ltd.
- Astra Zeneca plc
- GSK plc
- Serum Institute of India Pvt. Ltd.
- Merck & Co. Inc.
- Novasep
- Charles River Laboratories
- Waisman Biomanufacturing
- uniQure NV
- Creative-Biogene
- Addgene
- Aldevron
- Thermo Fisher Scientific Inc.
- Spark Therapeutics Inc.
- Others

第 12 章：360 度分析師視角

第 13 章：附錄

研究方法
參考
縮寫
免責聲明
聯絡我們

簡介目錄

Product Code: ANV5367

REPORT HIGHLIGHT

Viral vector vaccines market size was valued at US$ 850.43 Million in 2024, expanding at a CAGR of 15.93% from 2025 to 2032.

Viral vector vaccines use a harmless virus as a delivery system to introduce genetic material from a pathogen into the body. This genetic code instructs cells to produce a protein that triggers an immune response without causing disease. These vaccines mimic natural infection, training the immune system to recognize and fight the real virus if exposed later. They are widely used in preventing infectious diseases like COVID-19 and Ebola.

Viral Vector Vaccines Market- Market Dynamics

Increasing prevalence of infectious diseases to propel market demand

The rising incidence of infectious diseases such as COVID-19, influenza, and hepatitis is propelling the demand for effective vaccines. According to the World Health Organization (WHO), vaccines prevent 2 to 3 million deaths annually, highlighting their critical role in global health. In addition, continuous progress in genetic engineering has facilitated the development of more efficient viral vector vaccines. However, instances of adverse effects, although rare, have been reported, leading to public hesitance, which is predicted to hamper the market growth in the coming years. On the contrary, developing regions present significant growth opportunities due to improving healthcare infrastructure and rising awareness about vaccination.

Viral Vector Vaccines Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 15.93% over the forecast period (2025-2032)

Based on Disease segmentation, infectious diseases was predicted to show maximum market share in the year 2024

Based on Type segmentation, adenovirus was the leading Type in 2024

On the basis of region, North America was the leading revenue generator in 2024

Viral Vector Vaccines Market- Segmentation Analysis:

The Global Viral Vector Vaccines Market is segmented on the basis of Disease, Type, End User, and Region.

The market is divided into four categories based on Disease: infectious diseases, cancer, genetic disorders, and others. The infectious diseases segment is expected to hold the major market share in the global viral vector vaccines market during the forecast period. This dominance is primarily driven by the high global burden of infectious diseases and the proven effectiveness of viral vector platforms in developing vaccines against them.

The market is divided into five categories based on Type: adeno-associated virus (AAV), adenovirus, lentivirus, retrovirus, and others. The adenovirus segment is expected to account for the largest market share during the forecast period. This is mainly because adenoviruses are widely used due to their strong immunogenicity, ability to carry large genetic payloads, and suitability for rapid vaccine development.

Viral Vector Vaccines Market- Geographical Insights

The North America region holds the largest share of the global viral vector vaccines market. This dominance is attributed to its advanced healthcare infrastructure, substantial investments in research and development, and the presence of leading pharmaceutical and biotechnology companies. Besides, the Asia-Pacific region is projected to experience the fastest growth in the global market, driven by the increasing healthcare investments, a rising prevalence of infectious diseases, and growing awareness of advanced therapeutic options.

Viral Vector Vaccines Market- Competitive Landscape:

Rising global demand for effective and rapid-response vaccines is driving technological innovation and strategic investment. Companies are focusing on enhancing vector design, improving safety profiles, and expanding manufacturing capabilities to meet surging demand. Partnerships with research institutions and government bodies are common to accelerate development and regulatory approval. Additionally, players are diversifying product pipelines to include vaccines for emerging infectious diseases. Regional expansions and acquisitions are also being pursued to strengthen global presence and increase access to advanced vaccine platforms.

Recent Developments:

In June 2025, ImmunoPrecise Antibodies Ltd. identified a stable epitope common to all four dengue virus serotypes using its AI-powered LENSai(TM) platform. This breakthrough supports progress toward a universal dengue vaccine using epitope-based targeting.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL VIRAL VECTOR VACCINES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Advanced Bioscience Laboratories
Sanofi S.A.
C.H. Boehringer Sohn AG & Ko
Brammer Bio, LLC
GE Healthcare
Creative Biogene
Pfizer Inc.
Moderna Inc.
Sinovac Biotech Ltd.
CSL Ltd.
Astra Zeneca plc
GSK plc
Serum Institute of India Pvt. Ltd.
Merck & Co. Inc.
Novasep
Charles River Laboratories
Waisman Biomanufacturing
uniQure N.V.
Creative-Biogene
Addgene
Aldevron
Thermo Fisher Scientific Inc.
Spark Therapeutics Inc.
Others

GLOBAL VIRAL VECTOR VACCINES MARKET, BY DISEASE- MARKET ANALYSIS, 2019 - 2032

Infectious Diseases
Cancer
Genetic Disorders
Others

GLOBAL VIRAL VECTOR VACCINES MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

Adeno-associated virus (AAV)
Adenovirus
Lentivirus
Retrovirus
Others

GLOBAL VIRAL VECTOR VACCINES MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

Pharmaceutical and Biopharmaceutical Companies
Research Institutes

GLOBAL VIRAL VECTOR VACCINES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Viral Vector Vaccines Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Viral Vector Vaccines Market Snippet by Disease
- 2.1.2. Viral Vector Vaccines Market Snippet by Type
- 2.1.3. Viral Vector Vaccines Market Snippet by End User
- 2.1.4. Viral Vector Vaccines Market Snippet by Country
- 2.1.5. Viral Vector Vaccines Market Snippet by Region
2.2. Competitive Insights

3. Viral Vector Vaccines Key Market Trends

3.1. Viral Vector Vaccines Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Viral Vector Vaccines Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Viral Vector Vaccines Market Opportunities
3.4. Viral Vector Vaccines Market Future Trends

4. Viral Vector Vaccines Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Viral Vector Vaccines Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Viral Vector Vaccines Market Landscape

6.1. Viral Vector Vaccines Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Viral Vector Vaccines Market - By Disease

7.1. Overview
- 7.1.1. Segment Share Analysis, By Disease, 2024 & 2032 (%)
- 7.1.2. Infectious Diseases
- 7.1.3. Cancer
- 7.1.4. Genetic Disorders
- 7.1.5. Others

8. Viral Vector Vaccines Market - By Type

8.1. Overview
- 8.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
- 8.1.2. Adeno-associated virus (AAV)
- 8.1.3. Adenovirus
- 8.1.4. Lentivirus
- 8.1.5. Retrovirus
- 8.1.6. Others

9. Viral Vector Vaccines Market - By End User

9.1. Overview
- 9.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
- 9.1.2. Pharmaceutical and Biopharmaceutical Companies
- 9.1.3. Research Institutes

10. Viral Vector Vaccines Market- By Geography

10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
10.2. North America
- 10.2.1. Overview
- 10.2.2. Viral Vector Vaccines Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.2.7. U.S.
  - 10.2.7.1. Overview
  - 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.7.3. U.S. Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.2.7.4. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.2.7.5. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.2.8. Canada
  - 10.2.8.1. Overview
  - 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.8.3. Canada Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.2.8.4. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.2.8.5. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3. Europe
- 10.3.1. Overview
- 10.3.2. Viral Vector Vaccines Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.7. Germany
  - 10.3.7.1. Overview
  - 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.7.3. Germany Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.3.7.4. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.7.5. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.8. UK
  - 10.3.8.1. Overview
  - 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.8.3. UK Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.3.8.4. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.8.5. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.9. France
  - 10.3.9.1. Overview
  - 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.9.3. France Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.3.9.4. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.9.5. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.10. Italy
  - 10.3.10.1. Overview
  - 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.10.3. Italy Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.3.10.4. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.10.5. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.11. Spain
  - 10.3.11.1. Overview
  - 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.11.3. Spain Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.3.11.4. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.11.5. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.12. The Netherlands
  - 10.3.12.1. Overview
  - 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.12.3. The Netherlands Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.3.12.4. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.12.5. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.13. Sweden
  - 10.3.13.1. Overview
  - 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.13.3. Sweden Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.3.13.4. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.13.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.14. Russia
  - 10.3.14.1. Overview
  - 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.14.3. Russia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.3.14.4. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.14.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.15. Poland
  - 10.3.15.1. Overview
  - 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.15.3. Poland Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.3.15.4. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.15.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.16. Rest of Europe
  - 10.3.16.1. Overview
  - 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.16.3. Rest of the Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.3.16.4. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.16.5. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Viral Vector Vaccines Key Manufacturers in Asia Pacific
- 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.4.4. APAC Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.4.5. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.4.6. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.7. China
  - 10.4.7.1. Overview
  - 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.7.3. China Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.4.7.4. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.7.5. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.8. India
  - 10.4.8.1. Overview
  - 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.8.3. India Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.4.8.4. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.8.5. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.9. Japan
  - 10.4.9.1. Overview
  - 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.9.3. Japan Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.4.9.4. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.9.5. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.10. South Korea
  - 10.4.10.1. Overview
  - 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.10.3. South Korea Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.4.10.4. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.10.5. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.11. Australia
  - 10.4.11.1. Overview
  - 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.11.3. Australia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.4.11.4. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.11.5. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.12. Indonesia
  - 10.4.12.1. Overview
  - 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.12.3. Indonesia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.4.12.4. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.12.5. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.13. Thailand
  - 10.4.13.1. Overview
  - 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.13.3. Thailand Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.4.13.4. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.13.5. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.14. Philippines
  - 10.4.14.1. Overview
  - 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.14.3. Philippines Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.4.14.4. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.14.5. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.15. Rest of APAC
  - 10.4.15.1. Overview
  - 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.15.3. Rest of APAC Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.4.15.4. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.15.5. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.5. Latin America (LATAM)
- 10.5.1. Overview
- 10.5.2. Viral Vector Vaccines Key Manufacturers in Latin America
- 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.5.4. LATAM Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.5.5. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.5.6. LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.7. Brazil
  - 10.5.7.1. Overview
  - 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.7.3. Brazil Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.5.7.4. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.7.5. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.8. Mexico
  - 10.5.8.1. Overview
  - 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.8.3. Mexico Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.5.8.4. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.8.5. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.9. Argentina
  - 10.5.9.1. Overview
  - 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.9.3. Argentina Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.5.9.4. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.9.5. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.10. Colombia
  - 10.5.10.1. Overview
  - 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.10.3. Colombia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.5.10.4. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.10.5. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.11. Rest of LATAM
  - 10.5.11.1. Overview
  - 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.11.3. Rest of LATAM Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.5.11.4. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa (MEA)
- 10.6.1. Overview
- 10.6.2. Viral Vector Vaccines Key Manufacturers in Middle East and Africa
- 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.6.4. MEA Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.6.5. MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.6.6. MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.7. Saudi Arabia
  - 10.6.7.1. Overview
  - 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.7.3. Saudi Arabia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.6.7.4. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.8. UAE
  - 10.6.8.1. Overview
  - 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.8.3. UAE Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.6.8.4. UAE Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.8.5. UAE Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.9. Israel
  - 10.6.9.1. Overview
  - 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.9.3. Israel Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.6.9.4. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.9.5. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.10. Turkey
  - 10.6.10.1. Overview
  - 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.10.3. Turkey Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.6.10.4. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.10.5. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.11. Algeria
  - 10.6.11.1. Overview
  - 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.11.3. Algeria Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.6.11.4. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.11.5. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.12. Egypt
  - 10.6.12.1. Overview
  - 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.12.3. Egypt Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.6.12.4. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.12.5. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.13. Rest of MEA
  - 10.6.13.1. Overview
  - 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.13.3. Rest of MEA Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  - 10.6.13.4. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.13.5. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Viral Vector Vaccines Industry

11.1. Competitive Dashboard
- 11.1.1. Competitive Benchmarking
- 11.1.2. Competitive Positioning
11.2. Company Profiles
- 11.2.1. Advanced Bioscience Laboratories
- 11.2.2. Sanofi S.A.
- 11.2.3. C.H. Boehringer Sohn AG & Ko
- 11.2.4. Brammer Bio, LLC
- 11.2.5. GE Healthcare
- 11.2.6. Creative Biogene
- 11.2.7. Pfizer Inc.
- 11.2.8. Moderna Inc.
- 11.2.9. Sinovac Biotech Ltd.
- 11.2.10. CSL Ltd.
- 11.2.11. Astra Zeneca plc
- 11.2.12. GSK plc
- 11.2.13. Serum Institute of India Pvt. Ltd.
- 11.2.14. Merck & Co. Inc.
- 11.2.15. Novasep
- 11.2.16. Charles River Laboratories
- 11.2.17. Waisman Biomanufacturing
- 11.2.18. uniQure N.V.
- 11.2.19. Creative-Biogene
- 11.2.20. Addgene
- 11.2.21. Aldevron
- 11.2.22. Thermo Fisher Scientific Inc.
- 11.2.23. Spark Therapeutics Inc.
- 11.2.24. Others